[HTML][HTML] A randomised, double-blind, placebo-controlled, multi-centre, dose-range, proof-of-concept, 24-week treatment study of lanifibranor in adult subjects with non …
B Pierre, B Elisabetta, R Vlad, HM Philippe… - Contemporary Clinical …, 2020 - Elsevier
Background Non-alcoholic steatohepatitis (NASH), a multifactorial disease, can progress to
hepatic fibrosis and cirrhosis. The Peroxysomal Proliferator-Activated Receptors, PPARα …
hepatic fibrosis and cirrhosis. The Peroxysomal Proliferator-Activated Receptors, PPARα …
[HTML][HTML] A randomized, controlled trial of the pan-PPAR agonist lanifibranor in NASH
SM Francque, P Bedossa, V Ratziu… - … England Journal of …, 2021 - Mass Medical Soc
Background Management of nonalcoholic steatohepatitis (NASH) is an unmet clinical need.
Lanifibranor is a pan-PPAR (peroxisome proliferator–activated receptor) agonist that …
Lanifibranor is a pan-PPAR (peroxisome proliferator–activated receptor) agonist that …
The PanPPAR agonist lanifibranor induces both resolution of NASH and regression of fibrosis after 24 weeks of treatment in non-cirrhotic NASH: results of the native …
S Francque, P Bedossa, V Ratziu, Q Anstee… - Hepatology, 2020 - dial.uclouvain.be
Background: In NASH, disease progression results from a complex interplay of intra‐and
extra‐hepatic processes encompassing metabolic (adipose tissue dysfunction, insulin …
extra‐hepatic processes encompassing metabolic (adipose tissue dysfunction, insulin …
[HTML][HTML] Elafibranor, an agonist of the peroxisome proliferator− activated receptor− α and− δ, induces resolution of nonalcoholic steatohepatitis without fibrosis …
V Ratziu, SA Harrison, S Francque, P Bedossa… - Gastroenterology, 2016 - Elsevier
Background & Aims Elafibranor is an agonist of the peroxisome proliferator− activated
receptor-α and peroxisome proliferator− activated receptor-δ. Elafibranor improves insulin …
receptor-α and peroxisome proliferator− activated receptor-δ. Elafibranor improves insulin …
Elafibranor: a potential drug for the treatment of nonalcoholic steatohepatitis (NASH)
MJ Westerouen Van Meeteren, JPH Drenth… - Expert opinion on …, 2020 - Taylor & Francis
Introduction: Nonalcoholic fatty liver disease (NAFLD) encompasses a progressive disease
phenotype starting from simple steatosis, which can progress to nonalcoholic steatohepatitis …
phenotype starting from simple steatosis, which can progress to nonalcoholic steatohepatitis …
Current and emerging pharmacological options for the treatment of nonalcoholic steatohepatitis
SA Polyzos, ES Kang, C Boutari, EJ Rhee… - Metabolism, 2020 - Elsevier
Nonalcoholic fatty liver disease (NAFLD) is a highly prevalent disease and important unmet
medical need. Current guidelines recommend, under specific restrictions, pioglitazone or …
medical need. Current guidelines recommend, under specific restrictions, pioglitazone or …
[PDF][PDF] The new‐generation pan‐peroxisome proliferator‐activated receptor agonist IVA337 protects the liver from metabolic disorders and fibrosis
G Wettstein, JM Luccarini, L Poekes… - Hepatology …, 2017 - Wiley Online Library
IVA337 is a pan‐peroxisome proliferator‐activated receptor (PPAR) agonist with moderate
and well‐balanced activity on the three PPAR isoforms (α, γ, δ). PPARs are regulators of …
and well‐balanced activity on the three PPAR isoforms (α, γ, δ). PPARs are regulators of …
[HTML][HTML] TVB-2640 (FASN inhibitor) for the treatment of nonalcoholic steatohepatitis: FASCINATE-1, a randomized, placebo-controlled phase 2a trial
R Loomba, R Mohseni, KJ Lucas, JA Gutierrez… - Gastroenterology, 2021 - Elsevier
Background & Aims Increased de novo lipogenesis creates excess intrahepatic fat and
lipotoxins, propagating liver damage in nonalcoholic steatohepatitis. TVB-2640, a fatty acid …
lipotoxins, propagating liver damage in nonalcoholic steatohepatitis. TVB-2640, a fatty acid …
Safety and efficacy of once-weekly efruxifermin versus placebo in non-alcoholic steatohepatitis (HARMONY): a multicentre, randomised, double-blind, placebo …
Background Fibroblast growth factor 21 (FGF21) regulates metabolism and protects cells
against stress. Efruxifermin is a bivalent Fc–FGF21 analogue that replicates FGF21 agonism …
against stress. Efruxifermin is a bivalent Fc–FGF21 analogue that replicates FGF21 agonism …
[HTML][HTML] Efficacy and safety study of cenicriviroc for the treatment of non-alcoholic steatohepatitis in adult subjects with liver fibrosis: CENTAUR Phase 2b study design
Background Non-alcoholic steatohepatitis (NASH) is often accompanied by liver fibrosis,
which can progress to cirrhosis; CC chemokine receptors type 2 and 5 (CCR2/CCR5), which …
which can progress to cirrhosis; CC chemokine receptors type 2 and 5 (CCR2/CCR5), which …